Search
T1D can be a traumatic diagnosis for children and young people, and often involves strict adherence to painful treatments, comorbid mental health conditions, and shortened life expectancy.
The DiabHQ Patient Portal app is now available to WA children and families living with Type 1 diabetes.
Thanks to the generous support of West Australians, new funding from Channel 7’s Telethon Trust will help develop a much-needed clinical pathway to support families with kids who have early-stage type 1 diabetes (T1D).
Globally, nearly 9 million people are living with type 1 diabetes (T1D). Although the incidence of T1D is not affected by socioeconomic status, the development of complications and limited access to modern therapy is overrepresented in vulnerable populations. Diabetes technology, specifically continuous glucose monitoring and automated insulin delivery systems, are considered the gold standard for management of T1D, yet access to these technologies varies widely across countries and regions, and varies widely even within high-income countries.
with Dr Kate Lomax
Researchers from The Kids Research Institute Australia will share in almost $4 million in grants to continue groundbreaking research to tackle childhood cancer, asthma, respiratory viral infections and more.
The Rio Tinto Children's Diabetes Centre is a research centre that aims to improve the lives of children and young adults living with diabetes by bringing together research, education and clinical care.
The generous support of Western Australians through Channel 7’s Telethon is helping to fund life-changing child health research, with two The Kids Research Institute Australia researchers awarded significant grants.
To assess the real-world performance of MiniMed™ 780G for Australians with type 1 diabetes (T1D) following advanced hybrid closed loop (AHCL) activation and to evaluate the effect of changing from MiniMed 670/770G to 780G.
Technology use in type 1 diabetes (T1D) is impacted by socioeconomic status (SES). This analysis explored relationships between SES, glycemic outcomes, and technology use.